Ziping Wei, BlissBio CEO
Eisai’s cancer drug Halaven at the center of $2B pact with BlissBio, like its Bristol Myers ADC deal
Eisai plans to pay up to $2 billion to develop an antibody-drug conjugate with Chinese biotech Bliss Biopharmaceutical, and the Japanese …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
